A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy

Trial Details

NCT ID

NCT07071337

Phase

PHASE3

Sponsor

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Status

RECRUITING

Cancer Type

HER2 Negative Breast Cancer

Interventions

• SKB264
• Nab-paclitaxel
• Paclitaxel
• Capecitabine

Locations (sample)

• Beijing, Beijing Municipality, China|39.9075,116.39723
• Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

• Aged ≥ 18 and ≤ 75 years at the time of signing the ICF, male or female;
• Histologically and/or cytologically confirmed HR+/HER2- BC based on pathological reports from the most recent biopsy or other pathological specimens;
• Subjects must have radiologically documented disease progression during or after the most recent treatment prior to enrollment;
• No prior systemic chemotherapy for locally advanced, relapsed, or metastatic stages. Subjects who previously received adjuvant/neoadjuvant chemothe…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.